[自身免疫性获得的凝血因子缺乏症的诊断和治疗]
1Department of Hematology, Gunma University Hospital.
[Rinsho ketsueki] The Japanese journal of clinical hematology
|October 29, 2023
概括
自身免疫凝血因子缺乏症 (AiCFD) 是一种罕见的出血疾病,其中自身抗体向特定的因子. 治疗包括控制出血和抑制免疫系统以消除自身抗体.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 自身免疫凝血因子缺乏症 (AiCFD) 是一种获得性出血障碍.
- 它是由针对单个凝血因子的自身抗体引起的,最常见的是因子VIII (获得性血友病A).
- 自动抗体可以是中和 (抑制剂) 或非中和 (清除增强剂).
研究的目的:
- 提供对自身免疫凝血因子缺乏症的全面概述.
- 突出与AiCFD相关的诊断和治疗挑战.
- 为了强调医生对这种罕见疾病的认识增加的必要性.
主要方法:
- 关于自身免疫凝血因子缺乏症的文献综述.
- 分析治疗策略,包括静血和免疫抑制疗法.
- 讨论AiCFD的临床表现和管理.
主要成果:
- AiCFD几乎影响所有凝血因子和·维勒布兰德因子.
- 治疗需要量身定制的静血支持 (因子替代,输血,绕过药物) 和免疫抑制.
- 获得的血友病A是AiCFD的一个代表性例子.
结论:
- AiCFD需要一种双重的方法,即静血疗法和免疫抑制疗法.
- 有效的管理取决于确定具体的缺陷因素和量身定制治疗.
- 提高全科医生的意识对于及时诊断和管理AiCFD至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
723
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
723
Disorders of Hemostasis
963
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
963
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Coagulation
6.9K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K


